Conclusion
Our results were clear indicating the unmet need for characterization of
target PK exposures to inform HCQ dosing optimization in COVID-19.
Dosing optimization for HCQ in COVID-19 is still an unmet need. Efforts
in this sense are a prerequisite for best the benefit/risk balance.